Agilent Technologies, Inc. $A Stock Holdings Boosted by Mutual Advisors LLC

Mutual Advisors LLC raised its position in shares of Agilent Technologies, Inc. (NYSE:A) by 7.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,701 shares of the medical research company’s stock after purchasing an additional 522 shares during the quarter. Mutual Advisors LLC’s holdings in Agilent Technologies were worth $925,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Agilent Technologies by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company’s stock valued at $3,908,141,000 after purchasing an additional 240,965 shares in the last quarter. Pictet Asset Management Holding SA boosted its stake in shares of Agilent Technologies by 2.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company’s stock worth $624,888,000 after acquiring an additional 128,131 shares in the last quarter. Generation Investment Management LLP boosted its stake in shares of Agilent Technologies by 19.8% during the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock worth $582,976,000 after acquiring an additional 824,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Agilent Technologies by 18.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock worth $448,748,000 after acquiring an additional 604,124 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its stake in shares of Agilent Technologies by 3.6% during the 1st quarter. Impax Asset Management Group plc now owns 2,931,794 shares of the medical research company’s stock worth $342,961,000 after acquiring an additional 102,365 shares in the last quarter.

Agilent Technologies Price Performance

A opened at $142.01 on Friday. The stock has a fifty day moving average of $127.58 and a 200-day moving average of $117.84. The firm has a market capitalization of $40.26 billion, a P/E ratio of 33.34, a PEG ratio of 4.63 and a beta of 1.26. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $153.84. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.37. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th will be issued a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Tuesday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is currently 23.24%.

Analyst Ratings Changes

A has been the subject of several research reports. Rothschild & Co Redburn initiated coverage on Agilent Technologies in a research note on Wednesday, October 8th. They set a “buy” rating and a $165.00 price objective for the company. Robert W. Baird raised their price objective on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, August 28th. Evercore ISI raised their price objective on Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 7th. Rothschild Redb raised Agilent Technologies to a “strong-buy” rating in a research note on Wednesday, October 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Agilent Technologies in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Agilent Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.62.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.